Compare
Atossa Therapeutics, Inc. vs Verrica Pharmaceuticals Inc. vs Unicycive Therapeutics, Inc. vs Mereo BioPharma Group plc
| Latest fiscal year | Atossa Therapeutics, Inc. ATOS | Verrica Pharmaceuticals Inc. VRCA | Unicycive Therapeutics, Inc. UNCY | Mereo BioPharma Group plc MREO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $35.58M | n/a | $500.0K |
| Revenue growth (YoY) | n/a | +370.2% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -34.2% | n/a | n/m |
| Net margin | n/a | -50.3% | n/a | n/m |
| Net income | -$34.77M | -$17.89M | -$26.55M | -$41.88M |
| EPS (Diluted) | -$4.04 | -$1.68 | -$1.67 | -$0.05 |
| Operating cash flow | -$29.76M | -$17.63M | -$31.32M | -$30.97M |
| Free cash flow | -$29.79M | -$17.63M | -$31.34M | -$30.99M |
| Cash & equivalents | $41.30M | $30.15M | $29.20M | $40.99M |
| Total assets | $47.61M | $47.13M | $49.13M | $45.92M |
| Total liabilities | $8.26M | $22.39M | $18.94M | $5.00M |
| Shareholders' equity | $39.35M | $24.74M | $30.20M | $40.92M |
| Return on year-end equity | -88.4% | -72.3% | -87.9% | -102.4% |
| Shares outstanding | 8.61M | 17.18M | 22.11M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Atossa Therapeutics, Inc. | Verrica Pharmaceuticals Inc. | Unicycive Therapeutics, Inc. | Mereo BioPharma Group plc |
|---|---|---|---|---|
| Latest | $1.8K Ended 2015-12-31 | $35.58M Ended 2025-12-31 | $675.0K Ended 2023-12-31 | $500.0K Ended 2025-12-31 |
| 1 year earlier | $40.1K Ended 2014-12-31 | $7.57M Ended 2024-12-31 | $951.0K Ended 2022-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $632.6K Ended 2013-12-31 | $5.12M Ended 2023-12-31 | n/a | $10.00M Ended 2023-12-31 |
| 3 years earlier | $481.8K Ended 2012-12-31 | $9.03M Ended 2022-12-31 | n/a | $0 Ended 2022-12-31 |
| 4 years earlier | $1.5K Ended 2011-12-31 | $12.00M Ended 2021-12-31 | n/a | n/a |